Overview

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Status:
Recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating blood tumor cells (CTC) detection and CTC-based PD-L1 antibody immunofluorescence detection will be performed.

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Apatinib
Immune Checkpoint Inhibitors